The Groundbreaking Alzheimer’s Treatment Big Pharma Wants Hidden

Alzheimer’s disease is a debilitating and devastating condition that affects millions of people worldwide. It is a progressive brain disorder that causes memory loss, thinking and behavioral changes, and ultimately leads to the inability to carry out daily activities. Currently, there is no cure for Alzheimer’s disease, but there are treatments available that can help manage the symptoms. However, there is a groundbreaking treatment for Alzheimer’s disease that Big Pharma wants to keep hidden.

The treatment in question is called aducanumab, and it has been developed by the biotechnology company Biogen. Aducanumab works by targeting amyloid plaques, which are sticky clumps of protein that build up in the brain of people with Alzheimer’s disease. These plaques are believed to be one of the main causes of the disease, as they disrupt the communication between neurons and lead to brain cell death.

The development of aducanumab has been a long and challenging process. Biogen first started working on the drug in 2007, and after numerous clinical trials and setbacks, it was finally ready to be submitted for FDA approval in 2019. However, the FDA rejected the drug, stating that more evidence was needed to prove its effectiveness.

This rejection was a major blow not only to Biogen but also to millions of people who are affected by Alzheimer’s disease. Many patients and their families were hopeful that this drug could be a game-changer in the treatment of the disease. They saw aducanumab as a ray of hope in what seemed like a hopeless situation.

But what was even more shocking was the revelation that Big Pharma, specifically the pharmaceutical company Eisai, had been secretly working on a similar drug to aducanumab. This drug, called BAN2401, also targets amyloid plaques and showed promising results in clinical trials.

So why would Big Pharma want to keep aducanumab hidden? The answer is simple – money. If aducanumab was approved by the FDA, it would become the first drug to effectively treat Alzheimer’s disease, and Biogen would have a monopoly on the market. This would mean huge profits for the company, which would also have the power to set the price of the drug.

On the other hand, if BAN2401 was approved, it would compete with aducanumab and potentially drive down its price. This is a common tactic used by Big Pharma to protect their profits. They would rather keep a potentially life-changing treatment hidden than risk losing money to a competitor.

But the repercussions of this hidden treatment go far beyond profits. Alzheimer’s disease takes a toll not only on the patients but also on their families and caregivers. It is a disease that robs people of their memories and ultimately their independence. The lack of effective treatments means that patients and their families are left to deal with the devastating effects of the disease on their own.

Furthermore, the hidden treatment also raises questions about the integrity and ethics of the pharmaceutical industry. It is unacceptable that companies would put their profits above the well-being of patients who are desperately in need of effective treatments.

Fortunately, there is still hope for aducanumab to be approved and made available to those who need it. After the FDA rejection, Biogen reanalyzed the data from their trials and found that aducanumab did show promising results in slowing down the progression of Alzheimer’s disease. They have resubmitted the drug for FDA approval, and a decision is expected by June 2021.

In the meantime, it is crucial to bring attention to this groundbreaking treatment and demand transparency from Big Pharma. Patients and their families have the right to know about all potential treatments for Alzheimer’s disease, and they should not be denied access to a potentially life-changing drug due to corporate greed.

In conclusion, the groundbreaking Alzheimer’s treatment, aducanumab, is being hidden by Big Pharma for their financial gain. This hidden treatment not only has the potential to change the lives of millions of people affected by Alzheimer’s disease but also raises serious ethical concerns. It is time for the pharmaceutical industry to prioritize the well-being of patients over profits and make this treatment accessible to those who need it.